Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.
Pancreas Cancer
DRUG: 89Zr-panitumumab
Incidence of treatment emergent adverse events assessed by CTCAE v5, Safety is defined by the number of CTCAE v5 grade 2 or higher adverse events by Day 7 determined that are significant, definitely, probably or possibly related to 89Zr-panitumumab. Safety data will be summarized by grade, severity, and type., 7 days
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.